AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02349217 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Assessment
Description: Pain assessment administered at baseline and at follow up visit. Pain assessment involves submerging hand in cold water.
Study NCT02349217 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain Assessment
Description: Pain assessment administered at baseline and at follow up visit. Pain assessment involves submerging hand in cold water.
Study NCT02349217 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires completed at baseline and at follow up visit. Questionnaires ask about fatigue, mood, stress, social support, marital satisfaction, depression, and general demographics (age, race and so on). It should take about 1½ hours total to complete the questionnaires.
Study NCT02349217 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Questionnaires completed at baseline and at follow up visit. Questionnaires ask about fatigue, mood, stress, social support, marital satisfaction, depression, and general demographics (age, race and so on). It should take about 1½ hours total to complete the questionnaires.
Study NCT02349217 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurocognitive Tests
Description: Neurocognitive tests administered at baseline and at follow up visit. Tests to check memory and thinking abilities.
Study NCT02349217 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neurocognitive Tests
Description: Neurocognitive tests administered at baseline and at follow up visit. Tests to check memory and thinking abilities.
Study NCT02349217 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cortisol Tests
Description: Cortisol testing performed after baseline visit and at follow up visit. Participants asked to collect saliva samples for cortisol assays immediately, 30, 45, and 60 minutes after awakening (representing the cortisol awakening response) and at noon, 4 P.M. and 8 P.M.
Study NCT02349217 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cortisol Tests
Description: Cortisol testing performed after baseline visit and at follow up visit. Participants asked to collect saliva samples for cortisol assays immediately, 30, 45, and 60 minutes after awakening (representing the cortisol awakening response) and at noon, 4 P.M. and 8 P.M.
Study NCT02349217 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interviews
Description: Interviews conducted after follow up visit. These interviews are audio-taped and transcribed.
Study NCT02349217 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interviews
Description: Interviews conducted after follow up visit. These interviews are audio-taped and transcribed.
Study NCT04640662 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma
Description: Single-injection of 2 ml PRP into the lesion under ultrasound-guided
Study NCT04640662 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet-Rich Plasma
Description: Single-injection of 2 ml PRP into the lesion under ultrasound-guided
Study NCT04640662 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prolotherapy
Description: Single-injection of 2ml dextrose 16.5% into the lesion under ultrasound-guided
Study NCT04640662 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolotherapy
Description: Single-injection of 2ml dextrose 16.5% into the lesion under ultrasound-guided
Study NCT03023813 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Written material provided.
Study NCT03689686 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive Respiratory Support
Description: Physiological crossover prospective study comparing four study trials (20 mins) delivered in computer generated random order:~1. Standard Oxygen therapy with mask~2. HFNC flow 2l/Kg~3. HFNC flow 3l/Kg~4. Helmet CPAP
Study NCT04098484 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Trial
Description: Participants will abstain from exercise throughout a 3-month period
Study NCT04098484 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Trial
Description: Participants will abstain from exercise throughout a 3-month period
Study NCT04098484 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Trial
Description: Participants will execute a 3-month exercise training program
Study NCT04098484 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Trial
Description: Participants will execute a 3-month exercise training program
Study NCT01940172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birinapant
Description: Dose Escalation:~Dose Level (1) - 13 mg/m2 (twice a week for 3 of 4 weeks); Dose Level (-1) - 11 mg/m2 (twice a week for 3 of 4 weeks); Dose Level (2) - 13 mg/m2 (twice weekly for 4 weeks );
Study NCT01940172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conatumumab
Description: 10 mg/kg IV on Day 1 and 15 of each cycle
Study NCT01712724 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: combined resistance and aerobic training
Description: For the group randomized to AT+RT, Patients will gradually be progressed from 1-2 sets and then from 10-15 repetitions and then increase resistance by 1.6-5 kg or increase the exercise band level and then reduced repetitions to 10 and repeated this process.
Study NCT01712724 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: combined resistance and aerobic training
Description: For the group randomized to AT+RT, Patients will gradually be progressed from 1-2 sets and then from 10-15 repetitions and then increase resistance by 1.6-5 kg or increase the exercise band level and then reduced repetitions to 10 and repeated this process.
Study NCT01598129 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ONCOS-102
Description: GMCSF encoding 3/5 chimeric adenovirus for intratumoral and intravenous injection on day 1, 4, 8, 15, 29, 57, 85, 113 and 141 tested in three different dose cohorts (3x10E10, 1x10E11 and 3x10E11) in combination with low-dose metronomic cyclophosphamide.
Study NCT00918736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium hyaluronate
Description: 3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hyalgan) into the ankle joints.
Study NCT00838084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2811376
Description: Oral capsules
Study NCT00838084 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsules
Study NCT01991613 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: liquid protein supplement
Description: The liquid protein supplement is already in use. The purpose of this study is to determine whether using the supplement earlier will lead to improved growth.
Study NCT02661048 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CyberHeart System
Description: The CyberHeart system uses proprietary software to assist the cardiologist to contour ablation targets. Standard radiosurgical techniques are then used to accomplish ablation
Study NCT01251341 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Based Compassion Training
Description: Eight-week training in compassion meditation, using a protocol developed by Geshe Lobsang Negi, Ph.D. of Emory University
Study NCT01251341 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Attention Training
Description: Eight week training in mindful attention, using a protocol developed by B. Alan Wallace, Ph.D.
Study NCT01251341 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adult Health Education Curriculum
Description: Eight week training in health and wellness, using a curriculum developed specifically for this study.
Study NCT02303132 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ussing experiment
Description: fresh colon mucosa (biopsy) of all participants will be mounted in an Ussing chamber and exposed to NSAIDs / PPI / control.
Study NCT02028208 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ammoniated mercury
Description: Metal allergen panel containing ascending doses of ammoniated mercury and a negative control.
Study NCT02028208 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Aluminum chloride and aluminum lactate
Description: Metal allergen panel containing ascending doses of alumium chloride, aluminum lactate and a negative control.
Study NCT02028208 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sodium tetrachloropalladate
Description: Metal allergen panel containing ascending doses of sodium tetrachloropalladate and a negative control.
Study NCT02837107 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mind Master
Description: 80ml Mind Master / day for 8 weeks
Study NCT02837107 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 80ml a look-alike Placebo / day for 8 weeks
Study NCT01961726 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Coronary Sinus Delivery
Study NCT01961726 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30 mg dose of JVS-100
Description: Coronary Sinus Delivery
Study NCT01961726 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 30 mg dose of JVS-100
Description: Coronary Sinus Delivery
Study NCT02989519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micronized progesterone
Study NCT03667703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famotidine
Description: Patients will be randomized to either receive a placebo or famotidine (study drug).
Study NCT01961726 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 45 mg dose of JVS-100
Description: Coronary Sinus Delivery
Study NCT01961726 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 45 mg dose of JVS-100
Description: Coronary Sinus Delivery
Study NCT02609867 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flowise Cerebral Flow Diverter
Description: Flowise Cerebral Flow Diverter Placement
Study NCT01914341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Live music played on the pentatonically tuned children's harp
Study NCT02637349 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POST Intervention
Description: POST Intervention group will receive a tailored survivorship care plan (SCP) at the end of their active treatment. The SCP will be discussed with them. Patient will be asked about satisfaction with the end of treatment session.
Study NCT02637349 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: POST Treatment as Usual
Description: The POST control group may receive a survivorship care plan (SCP) as part of treatment as usual though it is not a usual procedure. They will be asked about their satisfaction with the end of treatment session.
Study NCT03679520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New programme
Description: Time for topics related to the time after birth and in reversed chronological order to give an early and joint focus on parenthood for both parents. Involving new parents to share their experiences of early parenthood with expectant parents. Introducing and using evidence-based websites in the sessions A breastfeeding preparation that gives tools to meet common challenges in the initial phase of breastfeeding. Based on principles for adult learning.~Sessions~1. Introduction, life-change of becoming a parent and co-parenting~2. Early parenthood~3. Breastfeeding, caring for the baby and early parenthood~4. and 5 Labour, birth and postnatal care
Study NCT03679520 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular programme
Description: Antenatal parental preparation as usual. As no guidelines exist the number of sessions may vary between 2 and 3 sessions and smaller variations in content may also occur.~Sessions~1. (or 1 and 2) Labour, birth and postnatal care~2. or 3 Breastfeeding, caring for the baby and early parenthood
Study NCT01903980 — intervention group
Intervention type: OTHER
Intervention: No intervention. It is a retrospective study
Description: No intervention. It is a retrospective study
Study NCT01641419 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 ml of saline added to 30 ml of ropivacaine 0.5% solution for nerve block
Study NCT01641419 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 4 mg
Description: 2 ml of dexamethasone 4 mg solution added to 30 ml of ropivacaine 0.5% solution for nerve block
Study NCT01641419 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 8 mg
Description: 2 ml of dexamethasone 8 mg solution added to 30 ml of ropivacaine 0.5% solution for nerve block
Study NCT03667703 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be randomized to either receive a placebo or famotidine (study drug).
Study NCT00311467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine, Interferon, Interleukin
Description: Capecitabine orally from day 1 to 14 at a dose of 1000 mg/m2 twice daily every 21 days.~Interferon-alpha subcutaneously on days 1 + 3 + 5 weeks 1 + 2 +6 + 7,11+12 at a dose of 6 MIU/d.~Interleukin-2 subcutaneously on days 1 to 4 in weeks 3 + 4 +8 + 9,13+14 at a dose of 4.5 MIU/day.~Group B~Patients randomized to group B will receive treatment according to the same treatment schedule and at the same dosages without capecitabine.~Efficacy evaluations will be performed every 14 weeks of treatment in both groups
Study NCT03395379 — intervention group
Intervention type: PROCEDURE
Intervention: RFA
Description: Radiofrequency ablation (RFA) is a medical procedure in which part of the electrical conduction system of the tumor is ablated using the heat generated from medium frequency alternating current.
Study NCT06517134 — intervention group
Intervention type: DRUG
Intervention: Antihypertensive Agents
Description: use of antihypertensive drugs
Study NCT01843855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin 9,39
Description: Exendin 9,39 is a competitive antagonist of endogenous GLP-1.
Study NCT01843855 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A saline infusion will be given to match the study drug infusion.
Study NCT00868101 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Description: Remote ischemic preconditioning was induced by four 5-minutes cycles of lower limb ischemia and reperfusion using a blood pressure cuff
Study NCT03715283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Ankle Strengthing Program
Description: Patients in this arm will be given a USB or DVD video with description of ankle dorsi- and plantar- flexion resistance band exercise. They will also be given an outlined plan for there exercises, progression and an exercise diary. In general patients will start with a low resistance and low reps, over the 4 weeks they will increase the repetitions at the same resistance band. After the 4 weeks they will have the option to escalate the band resistance or continue at the same resistance and repetitions until comfortable progressing. The same 4 week progression will be used for each resistance band over the 12 weeks.
Study NCT03715283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Patients in this arm will be directed to continue there standard care program. They will be asked to refrain from resistance exercise for 12 weeks.
Study NCT01459705 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure Therapy (PE)
Description: Prolonged exposure therapy will consist of 10 treatment sessions lasting 90 - 120 minutes each, with additional between-session homework assignments.
Study NCT01459705 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy (VRET)
Description: Virtual Reality Exposure Therapy will consist of 10 treatment sessions lasting 90 -120 minutes with additional between-session homework assignments.
Study NCT01459705 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Waitlist
Description: This group will refrain from psychotherapy until after the completion of the 5 weeks of study participation
Study NCT03777683 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement (OLIGOPIN)
Description: investigators obtained ethical approval from the Research Ethics Committees of the Mashhad University of medical sciences. investigators enroll 60 patients who are admitted to ICU at hospitals of university. All eligible patients or their first degree relatives give informed consent before participating. Participants are randomly (block stratification) divided in two groups. At the first visit, baseline data are gathered and intervention group (n=30) will receive Oligopin supplement. In order to control the confounding effect of food intake, both the control and the intervention group receive the standard formulas based on their daily required energy via enteral root feeding.
Study NCT03777683 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: investigators obtained ethical approval from the Research Ethics Committees of the Mashhad University of medical sciences. investigators enroll 60 patients who are admitted to ICU at hospitals of university. All eligible patients or their first degree relatives give informed consent before participating. Participants are randomly (block stratification) divided in two groups. At the first visit, baseline data are gathered and control group (n=30) will receive oral capsules containing 130 mg Microcrystalline Cellulose. In order to control the confounding effect of food intake, both the control and the intervention group receive the standard formulas based on their daily required energy via enteral root feeding.
Study NCT01276236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: FDA Recommended dosing will be used in this study. Subjects on an efavirenz or etravirine-based regimen will be dosed at 600 mg orally, twice per day, for 96 weeks.~Subjects on a ritonavir-boosted protease inhibitor based regimen (except for tipranavir/ritonavir) will be dosed at 150 mg orally, twice per day, for 96 weeks.~Subjects that are on regimens that do not include etravirine, efavirenz, or ritonavir will be dosed at 300mg orally, twice per day, for 96 weeks. These doses are based on the recommendations from the company based on drug-drug interactions.
Study NCT05836376 — intervention group
Intervention type: PROCEDURE
Intervention: Mitral valve annuloplasty
Description: implantation of a prosthetic ring to treat mitral valve regurgitation
Study NCT00845988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aripiprazole
Description: dosage form : po recommended dosage : more than 10mg/day duration : 28 weeks
Study NCT00845988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aripiprazole
Description: dosage form : po recommended dosage : more than 10mg/day duration : 28 weeks
Study NCT03034395 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Wide Local Excision
Description: Surgery
Study NCT03262415 — intervention group
Intervention type: DEVICE
Intervention: LabPatch Continuous Glucose Monitoring (CGM)
Description: 1. The patch device that will be applied to subjects' arms in this study is about 3 inches in length and one inch in width, with adhesive tape on the sides.~2. The LabPatch circuit chip lies on the underside of the bandage. The circuit is in the form of a small chip (approximately 15.7 mm \[0.618\] x 15.7 mm \[0.618\]) placed in contact with the skin. The chip has a telescopic micropipette which draws interstitial fluid to be analyzed for glucose levels. The chip is also able to measure skin temperature to ensure appropriate skin contact.~3. A wire that connects the chip to a laptop that continuously captures glucose data.
Study NCT01307969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 1,8 mL of the local anesthetic formulations were injected at the apex of the maxillary right canine.
Study NCT00653822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alefacept
Description: IC and SC
Study NCT00653822 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: IV and SC
Study NCT04139876 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Haemorrhoidectomy
Description: Patient operated in the lithotomy position. The external components are grasped by clamps using gentle traction. Diathermy is used for dissection and hemostasis. The skin is incised midway to one-third of the distance from the top of the pedicle, thus, minimizing the skin excision. The subdermal fascia continuing into a submucosal fascia covering the internal anal sphincter is identified as are fibers passing between the hemorrhoid (H) and this fascia. The H is dissected free from the underlying internal sphincter in this plane, leaving the sphincter unharmed. The anal mucosa is incised at the transition from anal mucosa to hemorrhoidal mucosa and only anal mucosa overlying the H is excised. Only the caudal part of the H is excised. With the H held with gentle traction it is divided at the anal orifice. There will thus be a residual part of the H intra-anally with its caudal end 1-2 cm proximal to the anal orifice.